Enzalutamide (XTANDI) has an unshakable position in the treatment of metastatic prostate cancer, and clinicians treating patients with advanced prostate cancer internationally are also very interested in enzalutamide. Familiar, becoming the standard of care for metastatic castration-resistant prostate cancer. Research shows that early first-line treatment of metastatic prostate cancer has higher antigen response rates, longer survival, and lower risk of fatigue.
Enzalutamide was jointly developed by Pfizer and Astellas. It was approved by the US FDA on August 31, 2012 for the treatment of metastatic adenocarcinoma. For resistant prostate cancer, the drug is branded as XTANDI. The drug is an oral preparation and does not require genetic testing before use. It is available on doctor prescription. Medixo Center offers 50% off on Enzalutamide cost in USA .
